French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Ability to provide informed consent
HCM diagnosis referred for CMR assessment.
Disqualifiers
Patients unable to provide informed consent,
Patients with a history of ischemic cardiomyopathy or myocarditis.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov